High dose Recombinant Trivalent Subunit Rotavirus Vaccine for gastroenteritis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Nov 2022: Trial registered, NCT05621655
  2. 8 Jan 2023: Trial started, NCT05621655

The trials

NCT05621655: Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers

State
Under way
Phase
Phase 2
People
1,512 taking part
Started
8 Jan 2023
Primary completion
29 Apr 2023
Arms
High dose in toddlers (7-71 months old, 3 doses), High dose in toddlers (7-71 months old, 2 doses), High dose in infants (6-12 weeks of age, 3 doses at 4-week intervals), High dose in infants (6-12 weeks of age, 3 doses at 8-week intervals)
Results
None posted
  1. 18 Nov 2022: Trial registered
  2. 8 Jan 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.